Total Voting Rights
RNS Number : 6343J
Vernalis PLC
30 June 2017
 

TOTAL VOTING RIGHTS

 

VERNALIS PLC (the "Company")

 

30 June 2017

 

Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,445,230 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

 

The total number of voting rights in the Company is therefore 526,445,230.

 

The above figure of 526,445,230 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.

 

-  ends  -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

Toby Gibbs

 

 

FTI Consulting:

 

+44 (0) 20 3727 1000

Ben Atwell

Simon Conway

Stephanie Cuthbert

 

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focused on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

 

For further information about Vernalis, please visit www.vernalis.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRUKVSRBSANUAR